TRXC TransEnterix Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TRXC TransEnterix

TRXC 0.348

+0.6%

Aug 21 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

From: bull_dozer	6/5/2018 5:03:31 PM
	of 13

Analysts Shed Light on Transenterix (TRXC) Following Home Run Approval for Senhance Transenterix (NYSE:TRXC) investors got a taste of excitement this morning with a win that came early for the Senhance robotic surgical system, which won a nod for expanded indications of use: laparoscopic inguinal hernia and cholecystectomy (gallbladder removal) procedures. Present-day, the company’s innovative Senhance System now has approvals under its belt for laparoscopic colorectal, gynecological, inguinal hernia, and cholecystectomy surgery. In reaction, shares are on a 10% leap today. Stifel analyst Rick Wise draws attention to the FDA nod that hit just around three months after TRXC’s mid-February filing as reassuring. Though the win was largely “expected,” Wise cheers that “the agency’s turn-around time is likely slightly ahead of expectations.” Predicting these “broader procedure indications could accelerate Senhance market adoption,” the analyst reiterates a Buy rating on TRXC stock with a $ price target, which suggests a close to 16% upside from current levels. (To watch Wise’s track record, click here) smarteranalyst.com Ladenburg Thalmann downgraded TransEnterix (NYSE: TRXC) from Buy to Neutral with a price target of $4.00 (from $3.50). Analyst Jeff Cohen steps the sideline as he believes the current valuation is fair compared with peers. The analyst believes a 8.25x valuation on estimated FY 2020 revenues is fair following the announcement that Senhance System has been approved by the FDA for expanded indications of use including laparoscopic inguinal hernia and laparoscopic cholecystectomy. streetinsider.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext